Kazley Michael John has filed 6 insider transactions across 1 company since October 2025.
Most recent transaction: a grant/award of 4118828 shares of NovaBay Pharmaceuticals, Inc. ($NBY) on March 31, 2026.
Activity breakdown: 1 open-market purchase and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | NovaBay Pharmaceuticals, Inc. | $NBY | Kazley Michael John | Chief Executive Officer | A | Restricted Stock Units (Time-Based) | 4118828 | $0.00 | 4,118,828.0000 | 126,010,749 | 9999.99% | 3.27% |
| March 31, 2026 | NovaBay Pharmaceuticals, Inc. | $NBY | Kazley Michael John | Chief Executive Officer | A | Restricted Stock Units (Performance-Based) | 7722802 | $0.00 | 7,722,802.0000 | 126,010,749 | 9999.99% | 6.13% |
| Oct. 21, 2025 | NovaBay Pharmaceuticals, Inc. | $NBY | Kazley Michael John | Chief Executive Officer | C | Common Stock | 56806080 | $0.00 | 56,806,080.0000 | 5,816,204 | 9999.99% | 100.00% |
| Oct. 16, 2025 | NovaBay Pharmaceuticals, Inc. | $NBY | Kazley Michael John | Chief Executive Officer | P | Pre-Funded Warrants (Right to Buy) | 2702703 | $0.00 | 2,702,703.0000 | 5,816,204 | 9999.99% | 46.47% |
| Oct. 16, 2025 | NovaBay Pharmaceuticals, Inc. | $NBY | Kazley Michael John | Chief Executive Officer | A | Series D Non-Voting Convertible Preferred Stock | 220663 | $0.00 | 220,663.0000 | 5,816,204 | 9999.99% | 3.79% |
| Oct. 16, 2025 | NovaBay Pharmaceuticals, Inc. | $NBY | Kazley Michael John | Chief Executive Officer | A | Series E Non-Voting Convertible Preferred Stock | 134375 | $0.00 | 134,375.0000 | 5,816,204 | 9999.99% | 2.31% |